Also, the cytotoxic treatment would have targeted the CML stem cells which are not’BCR/ABL oncogene addicted’ and are considered to be the contributors of subsequent resistance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.